ALPN News and Press, Alpine Immune Sciences Inc. From 08/12/21

The following slide deck was published by Alpine Immune Sciences, Inc. in conjunction with this event. For further details see: Alpine Immune Sciences (ALPN) Investor Presentation

Start Time: 16:30 End Time: 16:56 Alpine Immune Sciences, Inc. (ALPN) Q2 2021 Earnings Conference Call August 10, 2021, 16:30 PM ET Company Participants Mitchell Gold - Executive Chairman and CEO Stanford Peng - President and Head of Research and Development Paul Rickey - CFO Alex Sharif - Di...

- Conference call and webcast today at 4:30 p.m. ET - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update an...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2...

After Celldex tumbled back in 2018, the stock has now moved beyond recovery. The company recently posted strong Phase 1 data for its chronic urticaria drug (CDX-0159). At 2021 ASCO, Celldex presented acceptable data for its cancer medicine (CDX-527). For further details see:...

Alpine Immune Sciences (ALPN) shares rise more than 9% premarket after announcing that it has signed a clinical trial collaboration and supply agreement with Merck (MRK).The collaboration will evaluate the safety and efficacy of Alpine’s ALPN-202 in combination with Merc...

- First Patient Dosed in NEON-2 Clinical Trial - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a clinical trial collabor...

This selection article continues a four-year ad hoc test of published studies that the Russell reconstitution generates excess risk-adjusted returns. In my prior three-year study from 2017, abnormal gains were identified from the annual June rebalancing and some profitable strategies ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today that the first patient has been dosed in Synergy, a Phase 2 study of ALPN-101 in patie...

Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal , not only for Alzheimer's patients, but...